EX-99.1 2 dex991.htm INVESTOR PRESENTATION Investor Presentation
CONFIDENTIAL
1
Investor Presentation
Exhibit 99.1

CONFIDENTIAL
2
Safe Harbor Statement
This presentation
may
contain
statements
that
are
not
historical
facts
and
are
considered
“forward-looking”
within
the
meaning
of the
Private Securities Litigation Reform Act of 1995.  These forward-looking statements are identified by their use of the terms: “expect(s),”
“intend(s),”
“may,”
“plan(s),”
“should,”
“could,”
“will,”
“believe(s),”
“anticipate(s),”
“estimate(s),”
or similar terms.  Oracle Healthcare
Acquisition Corp. (“Oracle”
or the “Company”), Precision Therapeutics, Inc. (“PTI”) or their respective representatives may also make
similar forward-looking statements from time to time orally or in writing.  You are cautioned that these forward-looking statements are
subject to a number of risks, uncertainties, or other factors that may cause (and in some cases have caused) actual results to differ
materially from those described in the forward-looking statements.  These risks and uncertainties include, but are not limited to, the
following: the risk that the merger transaction described in this presentation may not be consummated in a timely manner, if at all; the
inability to
obtain
the
required
vote
for
approval
of
the
Company’s
stockholders
in
order
to
consummate
the
merger;
the
outcome
of
any
legal proceeding
instituted
against
the
Company
and/or
others
in
connection
with
the
proposed
merger;
the
failure
of
the
conditions
to the
consummation of the merger to be satisfied; the termination of the merger agreement prior to the consummation of the merger; the
businesses of the Company or PTI suffering as a result of uncertainty surrounding the merger, including, but not limited to, potential
difficulties in
employee
retention,
adverse
effects
on
client
or
customer
relationships
and
disruption
of
current
plans
or
operations,
or, if
the merger
agreement
is
terminated
or
the
merger
otherwise
fails
to
occur,
the
uncertainties
associated
with
any
anticipated,
potential or
actual subsequent transaction involving the Company or any liquidation of the Company; the diversion of the attention of the Company’s
and/or PTI’s
management from ongoing business operations; the enactment or imposition of future regulatory or legislative actions that
adversely affect the Company, PTI or any industry or jurisdiction in which any of them operates its business; the adverse effects of other
economic, business and/or competitive factors; and other risks detailed in the Company’s current filings with the Securities and Exchange
Commission, including,
without
limitation,
its
most
recent
filings
on
Form
10-K
or
Form
10-Q,
which
discuss
these
and
other
important
risk
factors concerning the Company’s operations.   These factors may not constitute all factors that could cause actual results to differ
materially from those discussed in any forward-looking statement.  Oracle and PTI operate in continually changing business environments
and new
factors
emerge
from
time
to
time.
The
Company
cannot
predict
such
factors
nor
can
it
assess
the
impact,
if
any,
of
such factors
on its
or
PTI’s
financial
position
or
their
respective
results
of
operations
or
whether
or
when
the
merger
will
be consummated. 
Accordingly, forward-looking statements should not be relied upon as a predictor of actual results.  Many of the factors that will determine
the Company’s future results or whether or when the merger will be consummated are beyond its ability to control or predict.  In light of
the significant uncertainties inherent in the forward-looking statements contained herein, you should not rely on forward-looking
statements.  Additional factors that may affect the future results of Oracle and/or PTI are set forth in the Company’s filings with the
Securities and
Exchange
Commission,
which
are
available
via
the
Internet
at
www.sec.gov.
Neither
Oracle,
PTI
nor
any
of their
respective representatives
undertakes
any
obligation
to
publicly
update
or
revise
any
forward-looking
statements,
whether
as
a
result of
new information, future events or otherwise the otherwise.

CONFIDENTIAL
3
Precision Therapeutics, Inc.
We are a diagnostics services company dedicated to providing physicians,
patients, and payors with actionable information to personalize cancer treatment
We do this through ChemoFx ®,  a proprietary live tumor cell-based platform that
measures an individual patient’s tumor sensitivity and resistance to a range of
therapeutic alternatives under consideration by the physician
The Opportunity
Over 1 million cases per year in the U.S. alone are treated with
chemotherapy
through a “trial and error”
based approach
This represents an annually recurring $3 billion U.S. opportunity to Precision for
our services

CONFIDENTIAL
4
Company Highlights
Addresses the critical need for personalized treatment in cancer
Has the technology platform to capture the market
Has established the benefits of the platform
Clinically validated
Prospective Medicare reimbursement for gynecologic cancers
Reproducible, automated and scalable
Successful commercial ramp is accelerating
Substantial cash will enable multiple growth opportunities

CONFIDENTIAL
5
Cancer Treatment is Ambiguous
*Guidelines of the National Comprehensive Cancer Network (NCCN)
Altretamine
Anastrozole
Bevacizumab
Carboplatin
Cisplatin
Cyclophosphamide
Docetaxel
Gemcitabine
Ifosamide
Irinotecan
Letrozole
Liposomal Doxorubicin
Melphalan
Oral Etoposide
Oxaliplatin
Paclitaxel
Tamoxifen
Topotecan
Vinorelbine
And combinations
Cisplatin/Vinorelbine
Cisplatin/Etoposide
Cisplatin/Vinblastine
Bevacizumab (in combo with others)
Cisplatin
Carboplatin
Paclitaxel
Docetaxel
Vinorelbine
Gemcitabine
Etoposide
Irinotecan
Vinblastine
Mitomycin
Ifosfamide
Pemetrexed
Erlotinib
Therapeutic choice is not clear cut in most
primary metastatic and recurrent cancers
Recurrent Ovarian Cancer Treatments
Non-Small Cell Lung Cancer
Treatments

CONFIDENTIAL
6
Critical Need for Personalized Treatment in Cancer
Drug A
Drug B
Drug C
Less than one in four patients respond to any given round of
chemotherapy
Response is inconsistent from one patient to another
Two patients with identical health histories and typed the “same”
through standard pathology techniques will respond differently to
the same drug
ChemoFx helps physicians select drugs that will work
Precision has the opportunity to impact this market similar to a
blockbuster drug

CONFIDENTIAL
7
ChemoFx

CONFIDENTIAL
8
Live Cell Platform
Live patient tumor cells contain all the information and integrate
the effects of all Genomics, Genetics, Proteomics and even
unknown factors
Single platform/process applicable across multiple classes of drugs and
multiple tumor types
Faster time to market with new products than pharmacogenomic approach
with minimal investment
Positions us well to incorporate new technologies and discoveries

CONFIDENTIAL
9
Right Approach to Capture the Market
We’ve successfully addressed the market needs
Provides information on what drug will work for my patient
Clinically validated
Dependably produces an actionable answer
Applicable to the majority of patients –
only requires biopsies

CONFIDENTIAL
10
ChemoFx Process
Isolate and Enrich Tumor Cell Population
Challenge Cells with Chemotherapy
Control Well
Enumerate Surviving Cells
Treated Well
Sample Response Curve
Interpret Results
0      1      2      3      4      5      6      7      8      9
10
Doses
1.25
1.00
0.75
0.50
0.25
0.00

CONFIDENTIAL
11
Different Patients Respond Differently to Same Drug
Multiple Patients’
Response Curves
Non-responsive
Intermediate
Responsive
Gemcitabine

CONFIDENTIAL
12
Personalized and Actionable Results
Straight-forward
information for physicians
Intuitively understandable by
patients

CONFIDENTIAL
13
Gallion
et al; Int
J
Gynecol
Cancer 2006
135 patient subset of 256 ovarian and peritoneal cancer patients
Approximately 3X longer PFI for patients treated with drugs classified as   
responsive vs. non-responsive
(p<0.01)
Heinzman, et al;
Pathology 2007
Cell culture process produced average increase in malignant cell
population of 37% (p<0.0001)
All
50
specimen
resulted
in
>
60%
malignant
cells
to
test
(p=0.01)
Ness R.B. et al;
AntiCancer
Research
2002
64% patients predicted to have a response achieved a response
100% patients predicted to have no response did not respond
21 specimens
Nickles
Fader; ASCO
abstract 2005
84 primary ovarian cancer patients
Platinum sensitive women had nearly 3X longer PFI than patients
treated with drugs classified as non-responsive
(p<0.007)
Pattern of Response
(3 papers)
In vitro
data was consistent with expected population response rates
276 primary ovarian specimens, 283 ovarian cancer explants and
148 breast specimens
Current Clinical Evidence

CONFIDENTIAL
14
ChemoFx Predicts Patient Response
Patients treated with a drug reported as responsive experienced a median progression-free
interval approximately 3 times longer
than patients treated with a drug reported as non-
responsive -
135 patient subset of 256 patients, p< 0.01
Most Current Clinical Evidence
Source: International Journal of Gynecologic Cancer (Jan–Feb 2006)
Ovarian Cancer
Non-responsive
Intermediate
Responsive
0
5
10
15
20
25
30
Progression Free Interval (months)

CONFIDENTIAL
15
We provide ChemoFx at a list price of $450 per drug or combination
Average invoiced price is approximately $3,300 and rising
Medicare
Prospectively paying for gynecologic cancers upon initial claim submission,
since 2Q06
Commercial reimbursement
Over 425 private payors have paid on a case-by-case basis
Reimbursement: A Success Story

CONFIDENTIAL
16
Market

CONFIDENTIAL
17
Solid tumor cancers treated with chemotherapy in which:
Multiple standards of care exist, or no standard exists
Choice of chemotherapy regimen is not clear-
common situation in primary metastatic
and recurrent cancers
Broad Market Opportunity
Average over $3,300 billed/test
Ovarian market
$250 million
All four >
$3 billion
Annual U.S. Market Opportunity for
Precision
Recurrent
Late-stage
Ovarian
Breast
Colorectal
Lung
$2,000
$1,500
$1,000
$500
$0
ChemoFx has been used
in over 30 different types
of cancer
$250M
$625M
$650M
$1,530M

CONFIDENTIAL
18
Strategy

CONFIDENTIAL
19
Broaden market adoption via direct sales to physicians
Expand market share in tumor types beyond gynecologic cancers
Add new drugs and biologics as they are approved
Establish ChemoFx as standard of care
Continue to grow the number of contracted payors
Leverage platform to develop next generation solutions
Corporate Strategy

CONFIDENTIAL
20
Initial sales focus on
gynecologic oncology
Establish presence within
hospitals
Develop relationships with
pathology and operating room
staffs
Expand presence in additional
tumor types by leveraging
process strengths in hospitals
Broaden Market Adoption via Direct Sales
450
400
350
300
250
200
150
100
50
0
20
18
16
14
12
10
8
6
4
2
0
Billed Tests
Sales Reps
Sales Force
Established
450
400
350
300
250
200
150
100
50
0
20
18
16
14
12
10
8
6
4
2
0
Billed Tests
Sales Reps
1Q06
2Q06
3Q06
3Q07
2Q07
1Q07
4Q06
450
400
350
300
250
200
150
100
50
0
20
18
16
14
12
10
8
6
4
2
0
Billed Tests
Sales Reps
400
350
300
250
200
150
100
50
0
20
18
16
14
12
10
8
6
4
2
0
Billed Tests
Sales Reps
1Q06
2Q06
3Q06
3Q07
2Q07
1Q07
4Q06

CONFIDENTIAL
21
Ovarian cancer
prospective trial:
PT-301
Yale University and various other sites
Progression-free survival and response endpoints
Physicians blinded to assay results
Breast cancer
prospective trial:
PT-205
Breast cancer
prospective trial:
PT-302
Breast cancer
prospective trial:
PT-304
Observational study
(The Registry)
Establish as the Standard of Care –
Ongoing Trials
US
Oncology
Research
-
34
patients
ChemoFx
embedded in clinical trial of new chemotherapy
Show preliminary demonstration of predictive value in breast cancer
NSABP (B-40) -
1200 patients
Neo-adjuvant breast cancer patients, randomized treatment with three
chemotherapies and with or without a biologic agent
Physicians blinded to results of assay
Tumor response endpoint
U.S. Department of Defense and University of Pittsburgh Cancer
Institute –
224 patients
Physicians blinded to the results of the assay
Ongoing study collecting clinical outcomes on commercial specimens
from participating physicians

CONFIDENTIAL
22
Additional
Chemos
Live Cell Platform
Targeted Therapies/Biologics
Pharmacogenomic
Tests
Enhance Diagnostic Product Offering
>
30
Tumor
Types

CONFIDENTIAL
23
Company Uniquely Positioned to be Ideal Development Partner
Platform:
Our
live
cell
platform
can
be
a
“gold
standard”
for
additional test development because it captures active, cycling
tumor cell behavior
People: We have become experts at sourcing tissue out of
facilities
Programs: Company has invested in an Observational Study that
is collecting consented patient samples and outcomes on a
portion of our commercial volume

CONFIDENTIAL
24
Sean McDonald
President and CEO
17 years experience leading
healthcare companies, founder of
Automated Healthcare and Group
President of McKesson Automation
Group
David Heilman
CFO
27 Years of financial experience with
GNC Corp. and First Westinghouse
Capital Corporation
Sharon Kim
V.P., Business Development
17 years in business development
and healthcare consulting at
McKesson and Deloitte Consulting
Michael Gabrin
CTO/CIO
21 years in technology and product
development, Vocollect, Inc.,
Westinghouse
Matthew Marshall
V.P., Sales and Marketing
22 years of sales experience at
McKesson, Automated Healthcare,
HBO & Company
Holly Gallion, M.D.
V.P., Clinical Affairs
24 years in gynecologic oncology at
Magee-Women’s Hospital/University
of Pittsburgh and University of
Kentucky
Perry Dimas
V.P., Payor Relations
10 years of securing reimbursement
for proprietary diagnostic products
including Cytyc and XDx
Alan Wells, M.D., D.M.Sc.
CSO
16 years in Pathology at University of
Pittsburgh and University of Alabama
at Birmingham
Management Team

CONFIDENTIAL
25
Post-Merger Board of Directors
Joel Adams
PTI Director since 2003
Founder, President and Managing
General Partner of Adams Capital
Management, Inc., a venture capital
Firm
Larry Feinberg
Chairman, Oracle Director since
2005
Founder and Managing General
Partner of Oracle Partners, L.P.;
President of Oracle Investment
Management
Kevin Johnson
PTI and Oracle Director since 2005
Former CEO, President, and
Chairman of DIANON Systems,
Inc.; Chairman of Aureon
Laboratories Inc.; Director of
MDdatacor, Inc.; Advisory board
member of New Leaf Venture
Partners
Rich Kollender
PTI Director since 2006
Principal and partner of Quaker
BioVentures; C.P.A. and Member of
American and Pennsylvania
Institutes of Certified Public
Accountants
Stan Lapidus
Chairman, PTI Director since 2001
Founder and CEO of Helicos
BioSciences Corporation; Founder
and former President of EXACT
Sciences Corporation and Cytyc
Corporation
Joel Liffmann
President, COO, Oracle Director
since 2005
Principal of Oracle Investment
Management; Member of Oracle
Strategic Capital, LLC
Per Lofberg
Oracle Director since 2005
President and CEO of Merck Capital
Ventures, LLC; Former President and
Chairman of Merck-Medco Managed
Care, LLC; Director of Cytel, Inc.;
Director of Ventiv Health, Inc.; Director
of  PHT, Inc.; Director of ImpactRx, Inc.
Sean McDonald
President, CEO and
PTI Director since 2001
Director of Respironics, Inc.; Founder of
Automated Healthcare and Group
President of McKesson Automation
Group
Ken Weisshaar
PTI Director since 2007
Board member of Orthofix International
N.V.; Former director of Digene
Corporation;  Former COO and Strategy
Advisor for Sensatex, Inc.; Former CFO
of Becton Dickinson & Co.

CONFIDENTIAL
26
Financial Overview

CONFIDENTIAL
27
Attractive Financial Model
Significant revenue growth
Attractive gross margins
Strong operating leverage
Low capital investment requirements

CONFIDENTIAL
28
Summary of Historical Financials
Years ended December 31,
Nine months ended
September 30,
2006
2007
2004
2005
2006
(unaudited)
(unaudited)
(In thousands, except for numbers of tests and per test amounts)
Number
of
tests
billed…………………………..
406
285
483
260
977
Average
net
revenue
per
test
billed………..
$776
$891
$1,064
$896
$1,672
Net revenues
from
tests
billed………………...
$315
$254
$514
$233
$1,634
Reversals
of
Medicare
claim
denials…………
1,234
1,666
332
161
37
Net revenues
1,549
1,920
846
394
1,671
Laboratory
Costs………………………...
984
978
1,078
735
1,327
Gross Profit…………………………………….
565
942
(232)
(341)
344
Gross Margin…………………………….
36%
49%
-27%
-87%
21%
Operating expenses:
Sales
and
marketing…………………….
$307
$376
$1,801
$999
$3,607
Research
and
development…………….
3,003
2,814
4,682
3,179
3,576
General
and
administrative……………..
2,752
2,282
2,452
1,521
2,729
Depreciation……………….……………..
243
226
171
137
139
Net
losses
from
Operations………………….
$(5,740)
$(4,756)
$(9,338)
$(6,177)
$(9,707)

CONFIDENTIAL
29
100
80
60
40
20
0
9.4
119.2
PTI Projected Revenue ($ Millions)
120
0
38.1
82.4
Projected Financials for PTI
2008 revenue growth based upon sales force expansion
2009 revenue growth based upon gynecologic market penetration and moderate increase in
contracted payors
2010-2011 reflect minimal market penetration in additional tumor types
40
30
20
10
0
-10
-20
-30
-40
(33.9)
3.9
(26.0)
PTI Projected EBITDA ($ Millions)
40
30
20
10
0
-10
-20
-30
-40
29.4
2008
2009
2010
2011
133%
CAGR
2011
2010
2009
2008

CONFIDENTIAL
30
September 30, 2007
Assuming
Maximum
Approval
(1)
Assuming
Minimum
Approval
(2)
(In thousands)
Cash and cash equivalents……………………................
$132,386
$108,987
Working capital…………………………………................
126,322
102,923
Total assets………………………………………..............
137,946
114,547
Long-term obligations (less current portion)…………….
3,339
3,339
Total
liabilities………………………………………………
10,834
10,834
Stockholders’
equity……………………………………….
127,112
103,713
Selected Pro Forma Condensed
Combined Balance Sheet Data
(1)
Assumes that no Oracle stockholders convert their shares of Oracle common stock into their pro rata share
of the amount held in the trust account.
(2)
Assumes that 19.99% of the issued and outstanding shares of Oracle common stock were voted against
the merger and that the holders of such shares of Oracle common stock properly elected to convert such
shares of common stock into a pro rata share of the amount held in the trust account.

CONFIDENTIAL
31
Company Highlights
Addresses the critical need for personalized treatment in cancer
Has the technology platform to capture the market
Has established the benefits of the platform
Clinically validated
Prospective Medicare reimbursement for gynecologic cancers
Reproducible, automated and scalable
Successful commercial ramp is accelerating
Substantial cash will enable multiple growth opportunities

CONFIDENTIAL
32
Appendix

CONFIDENTIAL
33
OHAC is a special purpose acquisition corporation (SPAC) formed in
September 2005
March 8, 2006: Raised $113.5M (net) in its IPO
–
15M units (1 common share + 1 warrant @ $6.00/share)
–
3.75M common shares and 833,334 warrants held by founders
December 31, 2007: Held $120M in trust
January 25, 2008:
Share price: $7.90
Warrant price: $0.37
Unit price: $8.15
PTI is a life sciences company developing and commercializing tests
intended to assist physicians individualize cancer therapy
December 3, 2007: OHAC signs a merger agreement with PTI, amended
on January 24, 2008
Shareholder vote scheduled for no later than March 8, 2008
Oracle
Healthcare
Acquisition
Corporation
(“OHAC”)
Transaction Summary
Precision
Therapeutics
Background
on the
Merger

CONFIDENTIAL
34
Offering Summary
19.0M shares of Oracle common stock issued for all outstanding PTI
shares
4.5M shares reserved for issuance upon exercising of outstanding
warrants and options
4.25M upon achievement of one of the following after the closing:
Trailing 12 month net revenues of at least $7M from the sale of services or
products for use in connection with non-gynecological cancers
Trailing
12
month
net
revenues
of
al
least
$40M
from
the
sale
of
services
or
products for any use
Cumulative
aggregate
net
revenues
of
at
least
$10M
from
the
sale
of
services
or
products for use in connection with non-gynecologic cancers
If market price is
less than
$7.78 per share 180 days after the closing,
Oracle either issues or reserves up to 6,666,667 shares for issuance
Prior to March 9
Base
Consideration
Milestone
Consideration
Top-up
Closing

CONFIDENTIAL
35
Transaction Terms
Date of Definitive Agreement: December 3, 2007
Market Capitalization: Pro forma capitalization will include:
PTI Transaction Value:
Conditions to Close:
Shareholder approval: less than 20% of Oracle stockholders requesting
redemption
Customary closing conditions for transactions of this nature
(1)
Current Oracle shares outstanding does not include outstanding warrants
(2)
Shares issued to PTI does not include milestone payment of 4.25M shares
and top-up consideration of up to 6.67M shares
Current
Oracle
Shares
Outstanding 
Shares Issued
for PTI Common
Stock
(2)
Shares
Reserved for
PTI Options
and Warrants
Post Merger Fully-
Diluted
Shares Outstanding
Oracle
Share Price
(1/25/2008)
Post Merger
Market
Capitalization
18,750,000
+
19,000,000
+
4,500,000
=
42,250,000
X
$7.90
=
$333,775,000
Total Oracle
Shares
Issued /
Reserved
(2)
Oracle Share
Price
(1/25/2008)
Total PTI
Transaction
Equity Value
23,500,000
X
$7.90
=
$185,650,000
(1)

CONFIDENTIAL
36
Pro Forma Ownership
Note:
PTI ownership consists of 19.0M shares; does not
include milestone payment of 4.25M shares, top-up
consideration of 6.67M shares, and 4.5M shares
reserved for PTI options and warrants
Note:
PTI ownership consists of 23.5M shares; does not
include milestone payment of 4.25M shares and top-up
consideration of up to 6.67M shares
Oracle shares includes exercise of 15.0M warrants
SPAC Founders Shares includes exercise of 0.834M
warrants
PTI Common
Shareholders
50.4%
Oracle Public
Shareholders
39.7%
SPAC Founders Shares
9.9%
PTI Common
Shareholders
40.5%
Oracle Public
Shareholders
51.6%
SPAC Founders Shares
7.9%
Assuming No Exercise of
Oracle or PTI Warrants
Assuming Full Exercise of
Oracle or PTI Warrants